SciELO - Scientific Electronic Library Online

 
vol.133 issue3Antiphospholipid antibodies in idiopathic membranous nephropathySeroprevalence of herpes simplex virus type 2 (HSV-2) infection in two clinics for sexually transmitted diseases in Santiago, Chile author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

Share


Revista médica de Chile

Print version ISSN 0034-9887

Abstract

AFANI S, Alejandro et al. Primary resistance to antiretroviral therapy in patients with HIV/AIDS in Chile. Rev. méd. Chile [online]. 2005, vol.133, n.3, pp.295-301. ISSN 0034-9887.  http://dx.doi.org/10.4067/S0034-98872005000300004.

Background: Resistance to antiretroviral therapy is a determining factor for therapeutic failure in HIV/AIDS. The prevalence of primary resistance (i.e. in those patients that have not received treatment) varies in different parts of the world. Aim: To study the prevalence of primary resistance to antiretroviral drugs in patients living in Northern Santiago. Patients and methods: Viral load, lymphocyte subpopulations by flow cytometry and genotypic resistance testing were assessed in blood samples from 60 HIV-1 infected patients (mean age 37 years, 54 male). Results: Mean CD4 cell count and viral load was 200 cells/ml and 142,840 RNA copies/ml respectively. Ten mutations were identified: V179D, L10I/V, M361, L63P, A71T/V, Y115F, V118I and K20R. None of these mutations is associated to a high degree of resistance to reverse transcriptase inhibitors, nucleoside analogs (NRTI), non nucleoside analogs (NNRTI) or viral protease inhibitors. Conclusions: This is a first approach to study antiretroviral resistance in Chilean patients. This study must be amplified, since the prevalence of resistance may experience changes with time (Rev Méd Chile 2005; 133: 295-301)

Keywords : Acquired immunodeficiency syndrome; Antiretroviral therapy, highly active; HIV infections.

        · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License